A Phase 3 interventional study of 20vPnC in Pneumococcal Disease, sponsored by Pfizer. Completed at 43 sites in United States. Open to participants aged 15 Months to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-22.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.
Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 9th largest by enrollment, is one of 5 that started in 2020, is one of 14 in phase 3, and was the 8th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 42 days–98 days · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in United States
Ages 2 mo–15 mo · Healthy volunteers
By country, each count listing its studies:
Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 15 Months to 17 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 5 started in 2020.
This study's enrollment of 839 is above the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 668 across the 19 interventional studies. Of the 15 that completed or were terminated, 13 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 4 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 23rd largest by enrollment of the 57 interventional ones that give a count, is one of 6 that started in 2020, is one of 33 in phase 3, and was the 54th registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
1 of the studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07023081PfizerA Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant | 2027-06-10 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the safety and immunogenicity of 20vPnC in healthy children 15 months through 17 years of age
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
20vPnC
Biological: 20vPnC
20vPnC
Biological: 20vPnC
20vPnC
Biological: 20vPnC
20vPnC
Biological: 20vPnC
20-valent pneumococcal conjugate vaccine
Percentage of Participants Reporting Prompted Local Reactions Within 7 Days After Vaccination
Local reactions included redness, swelling and, pain at the injection site, recorded by parent's/legal guardians of participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. One measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild: \> 0.0 to 2.0 cm, moderate: \>2.0 to 7.0 cm and severe: \>7.0 cm. Pain at the injection site was graded as mild: hurt if gently touched (cohort 1) and did not interfere with activity (cohort 2-4); moderate: hurt if gently touched with crying (cohort 1) and interfered with daily activity (cohort 2-4) and; severe: limited limb movement (cohort 1) and prevented daily activity (cohort 2-4). 95 percent (%) confidence interval (CI) was based on Clopper and Pearson method.
Time frame: Within 7 days after vaccination on Day 1
Percentage of Participants Reporting Prompted Systemic Events Within 7 Days After Vaccination: Cohort 1
Systemic events for Cohort 1 included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature \>=38.0 degrees Celsius (C) and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0-degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.
Time frame: Within 7 days after vaccination on Day 1
Percentage of Participants Reporting Prompted Systemic Events Within 7 Days After Vaccination: Cohorts 2, 3 and 4
Systemic events for Cohort 2-4 included fever, fatigue, headache, muscle pain and joint pain, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature \>=38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Fatigue, headache, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (prevents daily routine activity). 95% CI was based on Clopper and Pearson method.
Time frame: Within 7 days after vaccination on Day 1
Percentage of Participants Reporting Adverse Events (AEs) up to 1 Month After Vaccination
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From vaccination (on Day 1) up to 1 month after vaccination
Percentage of Participants Reporting Serious Adverse Events (SAEs) up to 6 Months After Vaccination
An SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. 95% CI was based on the Clopper and Pearson method.
Time frame: From vaccination (on Day 1) up to 6 months after vaccination
Percentage of Participants Reporting Newly Diagnosed Chronic Medical Conditions (NDCMCs) up to 6 Months After Vaccination
An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. 95% CI was based on the Clopper and Pearson method.
Time frame: From vaccination (on Day 1) up to 6 months after vaccination
Geometric Mean Fold Rises (GMFRs) of Pneumococcal Serotype-Specific Immunoglobulin G (IgG) Concentrations for the 7 Additional Serotypes From Before to 1 Month After 20vPnC Vaccination: Cohort 1 and 2
Pneumococcal serotype-specific IgG concentrations were measured from serum samples for the 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding 2-sided 95% CIs (based on Student's t distribution). Superiority of IgG concentration 1 month after 20vPnC to before vaccination for each serotype was demonstrated if the 95% lower CI of GMFR was \>1.
Time frame: Before vaccination on Day 1 to 1 month after vaccination
GMFRs of Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers for the 7 Additional Serotypes From Before to 1 Month After 20vPnC Vaccination: Cohort 3 and 4
Pneumococcal serotype-specific OPA titers were measured from serum samples for 7 the additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding 2-sided 95% CIs (based on the Student's t distribution). Superiority of OPA titers 1 month after 20vPnC to before vaccination for each serotype was demonstrated if the 95% lower CI of the GMFR was \>1.
Time frame: Before vaccination on Day 1 to 1 month after vaccination
Percentage of Participants With Predefined Levels of Pneumococcal Serotype-Specific IgG Concentrations for the 7 Additional Serotypes at 1 Month After Vaccination in Cohort 1 Only
Pneumococcal serotype-specific IgG concentrations were measured from serum samples for the 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. Percentage of participants with predefined level (\>=0.35 micrograms per milliliter) of IgG concentration for the 7 additional 20vPnC serotypes was presented. 2-sided 95% CI was based on Clopper and Pearson method.
Time frame: At 1 Month after vaccination on Day 1
Percentage of Participants With >=4-fold Rise in Pneumococcal Serotype-Specific OPA Titers for the 7 Additional Serotypes From Before to 1 Month After Vaccination: Cohorts 2, 3, and 4 Only
Pneumococcal serotype-specific OPA titers were measured from serum samples for 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. Percentage of participants with \>=4-fold rise in serotype-specific OPA titers from before vaccination to 1 month after vaccination with 20vPnC and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented. OPA titers were measured in a randomized subset of samples in Cohort 2 for this outcome measure.
Time frame: Before vaccination on Day 1 to 1 month after vaccination
Geometric Mean Concentrations (GMCs) of Pneumococcal Serotype-Specific IgG for the 20vPnC Serotypes Before and 1 Month After Vaccination
Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F; and 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMCs the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding 2-sided 95% CIs (based on the Student's t distribution).
Time frame: Before vaccination and 1 month after vaccination
GMFRs of Pneumococcal Serotype-Specific IgG Concentrations for the 13vPnC Serotypes From Before to 1 Month After Vaccination: Cohort 1 and 2
Pneumococcal serotype-specific IgG concentrations were measured from serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding 2-sided 95% CIs (based on the Student's t distribution).
Time frame: Before vaccination on Day 1 to 1 month after vaccination
GMFRs of Pneumococcal Serotype-Specific IgG Concentrations for the 20vPnC Serotypes From Before to 1 Month After Vaccination: Cohort 3 and 4
Pneumococcal serotype-specific IgG concentrations were measured from serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F; and 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding 2-sided 95% CIs (based on the Student's t distribution).
Time frame: Before vaccination on Day 1 to 1 month after vaccination
Geometric Mean Titers (GMTs) of Pneumococcal Serotype-Specific OPA Titers for the 20vPnC Serotypes Before and 1 Month After Vaccination
Pneumococcal serotype-specific OPA titers were measured from serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F; and 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding 2-sided 95% CIs (based on the Student's t distribution). OPA titers were measured in a randomized subset of serum samples in Cohorts 1 and 2. OPA titers for the 13vPnC serotypes were measured in a randomized subset of serum samples in Cohorts 3 and 4.
Time frame: Before vaccination on Day 1 and 1 month after vaccination
GMFRs of Pneumococcal Serotype-Specific OPA Titers for the 20vPnC Serotypes From Before to 1 Month After Vaccination: Cohorts 1 and 2
Pneumococcal serotype-specific OPA titers were measured from serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F; and 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding 2-sided 95% CIs (based on the Student's t distribution). OPA titers measured in a randomized subset of serum samples in Cohorts 1 and 2 for this outcome measure.
Time frame: Before vaccination on Day 1 to 1 month after vaccination
GMFRs of Pneumococcal Serotype-Specific OPA Titers for the 13vPnC Serotypes From Before to 1 Month After Vaccination: Cohorts 3 and 4
Pneumococcal serotype-specific OPA titers were measured for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding 2-sided 95% CIs (based on the Student's t distribution). OPA titers for the 13vPnC serotypes were measured in a randomized subset of serum samples in Cohorts 3 and 4.
Time frame: Before vaccination on Day 1 to 1 month after vaccination
| Milestone | Cohort 1: 20vPnC: >=15 to <24 Months | Cohort 2: 20vPnC: >=2 to <5 Years | Cohort 3: 20vPnC: >=5 to <10 Years | Cohort 4: 20vPnC: >=10 to <18 Years |
|---|---|---|---|---|
| Started | 210 | 219 | 203 | 207 |
| Vaccinated | 209 | 216 | 201 | 205 |
| Completed | 207 | 210 | 199 | 203 |
| Not completed | 3 | 9 | 4 | 4 |
| Withdrew: Lost to follow-up | 2 | 5 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 4 | 1 | 2 |
| Withdrew: Other | 0 | 0 | 0 | 1 |
| Withdrew: No longer met eligibility criteria | 1 | 0 | 1 | 1 |
Local reactions included redness, swelling and, pain at the injection site, recorded by parent's/legal guardians of participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. One measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild: \> 0.0 to 2.0 cm, moderate: \>2.0 to 7.0 cm and severe: \>7.0 cm. Pain at the injection site was graded as mild: hurt if gently touched (cohort 1) and did not interfere with activity (cohort 2-4); moderate: hurt if gently touched with crying (cohort 1) and interfered with daily activity (cohort 2-4) and; severe: limited limb movement (cohort 1) and prevented daily activity (cohort 2-4). 95 percent (%) confidence interval (CI) was based on Clopper and Pearson method.
| Percentage of participants | Cohort 1: 20vPnC: >=15 to <24 Months | Cohort 2: 20vPnC: >=2 to <5 Years | Cohort 3: 20vPnC: >=5 to <10 Years | Cohort 4: 20vPnC: >=10 to <18 Years |
|---|---|---|---|---|
| Redness: Any | 37.7 (31.1 to 44.8) | 39.1 (32.5 to 45.9) | 37.2 (30.5 to 44.3) | 15.1 (10.5 to 20.8) |
| Redness: Mild | 30.4 (24.2 to 37.2) | 22.8 (17.4 to 29.0) | 16.6 (11.7 to 22.5) | 10.7 (6.8 to 15.8) |
| Redness: Moderate | 7.4 (4.2 to 11.8) | 15.3 (10.8 to 20.9) | 18.6 (13.4 to 24.7) | 3.9 (1.7 to 7.5) |
| Redness: Severe | 0 (0.0 to 1.8) | 0.9 (0.1 to 3.3) | 2.0 (0.6 to 5.1) | 0.5 (0.0 to 2.7) |
| Swelling: Any | 22.1 (16.6 to 28.4) | 23.3 (17.8 to 29.5) | 27.1 (21.1 to 33.9) | 15.6 (10.9 to 21.3) |
| Swelling: Mild | 15.7 (11.0 to 21.4) | 11.6 (7.7 to 16.7) | 10.6 (6.7 to 15.7) | 5.4 (2.7 to 9.4) |
| Swelling: Moderate | 6.4 (3.4 to 10.7) | 11.2 (7.3 to 16.2) | 15.6 (10.8 to 21.4) | 10.2 (6.5 to 15.2) |
| Swelling: Severe | 0 (0.0 to 1.8) | 0.5 (0.0 to 2.6) | 1.0 (0.1 to 3.6) | 0 (0.0 to 1.8) |
| Pain at the injection site: Any | 52.5 (45.4 to 59.5) | 66.0 (59.3 to 72.3) | 82.9 (77.0 to 87.9) | 82.0 (76.0 to 87.0) |
| Pain at the injection site: Mild | 41.7 (34.8 to 48.8) | 47.0 (40.2 to 53.9) | 56.8 (49.6 to 63.8) | 62.9 (55.9 to 69.6) |
| Pain at the injection site: Moderate | 9.8 (6.1 to 14.7) | 17.7 (12.8 to 23.4) | 24.6 (18.8 to 31.2) | 17.6 (12.6 to 23.5) |
| Pain at the injection site: Severe | 1.0 (0.1 to 3.5) | 1.4 (0.3 to 4.0) | 1.5 (0.3 to 4.3) | 1.5 (0.3 to 4.2) |
Systemic events for Cohort 1 included fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature \>=38.0 degrees Celsius (C) and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0-degrees C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Cohort 1: 20vPnC: >=15 to <24 Months |
|---|---|
| Fever: >=38.0 degrees C | 11.8 (7.7 to 17.0) |
| Fever: >=38.0 degrees C to 38.4 degrees C | 5.9 (3.1 to 10.0) |
| Fever: >38.4 degrees C to 38.9 degrees C | 2.9 (1.1 to 6.3) |
| Fever: >38.9 degrees C to 40.0 degrees C | 2.9 (1.1 to 6.3) |
| Fever: >40.0 degrees C | 0 (0.0 to 1.8) |
| Decreased appetite: Any | 25.0 (19.2 to 31.5) |
| Decreased appetite: Mild | 17.6 (12.7 to 23.6) |
| Decreased appetite: Moderate | 6.4 (3.4 to 10.7) |
| Decreased appetite: Severe | 1.0 (0.1 to 3.5) |
| Drowsiness/increased sleep: Any | 41.7 (34.8 to 48.8) |
| Drowsiness/increased sleep: Mild | 31.4 (25.1 to 38.2) |
| Drowsiness/increased sleep: Moderate | 9.3 (5.7 to 14.2) |
| Drowsiness/increased sleep: Severe | 1.0 (0.1 to 3.5) |
| Irritability: Any | 61.8 (54.7 to 68.5) |
| Irritability: Mild | 22.5 (17.0 to 28.9) |
| Irritability: Moderate | 37.3 (30.6 to 44.3) |
| Irritability: Severe | 2.0 (0.5 to 4.9) |
Systemic events for Cohort 2-4 included fever, fatigue, headache, muscle pain and joint pain, recorded by parents/legal guardians of participant's using an e-diary. Fever was defined as temperature \>=38.0 degrees C and categorized as \>=38.0 to 38.4 degrees C, \>38.4 to 38.9 degrees C, \>38.9 to 40.0 degrees C and \>40.0 degrees C. Fatigue, headache, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (prevents daily routine activity). 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Cohort 2: 20vPnC: >=2 to <5 Years | Cohort 3: 20vPnC: >=5 to <10 Years | Cohort 4: 20vPnC: >=10 to <18 Years |
|---|---|---|---|
| Fever: >=38.0 degrees C | 3.3 (1.3 to 6.6) | 0.5 (0.0 to 2.8) | 0 (0.0 to 1.8) |
| Fever: >=38.0 degrees C to 38.4 degrees C | 1.4 (0.3 to 4.0) | 0.5 (0.0 to 2.8) | 0 (0.0 to 1.8) |
| Fever: >38.4 degrees C to 38.9 degrees C | 1.4 (0.3 to 4.0) | 0 (0.0 to 1.8) | 0 (0.0 to 1.8) |
| Fever: >38.9 degrees C to 40.0 degrees C | 0.5 (0.0 to 2.6) | 0 (0.0 to 1.8) | 0 (0.0 to 1.8) |
| Fever: >40.0 degrees C | 0 (0.0 to 1.7) | 0 (0.0 to 1.8) | 0 (0.0 to 1.8) |
| Fatigue: Any | 37.2 (30.7 to 44.0) | 28.1 (22.0 to 34.9) | 27.8 (21.8 to 34.5) |
| Fatigue: Mild | 21.9 (16.5 to 28.0) | 19.1 (13.9 to 25.3) | 15.6 (10.9 to 21.3) |
| Fatigue: Moderate | 14.4 (10.0 to 19.8) | 8.5 (5.1 to 13.3) | 12.2 (8.0 to 17.5) |
| Fatigue: Severe | 0.9 (0.1 to 3.3) | 0.5 (0.0 to 2.8) | 0 (0.0 to 1.8) |
| Headache: Any | 5.6 (2.9 to 9.5) | 18.6 (13.4 to 24.7) | 29.3 (23.1 to 36.0) |
| Headache: Mild | 3.3 (1.3 to 6.6) | 14.6 (10.0 to 20.3) | 20.0 (14.8 to 26.1) |
| Headache: Moderate | 1.9 (0.5 to 4.7) | 3.0 (1.1 to 6.4) | 7.8 (4.5 to 12.4) |
| Headache: Severe | 0.5 (0.0 to 2.6) | 1.0 (0.1 to 3.6) | 1.5 (0.3 to 4.2) |
| Muscle pain: Any | 26.5 (20.7 to 32.9) | 39.2 (32.4 to 46.3) | 48.3 (41.3 to 55.4) |
| Muscle pain: Mild | 17.7 (12.8 to 23.4) | 26.6 (20.6 to 33.3) | 34.6 (28.1 to 41.6) |
| Muscle pain: Moderate | 8.4 (5.0 to 12.9) | 11.1 (7.1 to 16.3) | 13.2 (8.9 to 18.6) |
| Muscle pain: Severe | 0.5 (0.0 to 2.6) | 1.5 (0.3 to 4.3) | 0.5 (0.0 to 2.7) |
| Joint pain: Any | 3.7 (1.6 to 7.2) | 6.5 (3.5 to 10.9) | 8.3 (4.9 to 12.9) |
| Joint pain: Mild | 2.3 (0.8 to 5.3) | 3.0 (1.1 to 6.4) | 3.4 (1.4 to 6.9) |
| Joint pain: Moderate | 1.4 (0.3 to 4.0) | 3.0 (1.1 to 6.4) | 4.9 (2.4 to 8.8) |
| Joint pain: Severe | 0 (0.0 to 1.7) | 0.5 (0.0 to 2.8) | 0 (0.0 to 1.8) |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Cohort 1: 20vPnC: >=15 to <24 Months | Cohort 2: 20vPnC: >=2 to <5 Years | Cohort 3: 20vPnC: >=5 to <10 Years | Cohort 4: 20vPnC: >=10 to <18 Years |
|---|---|---|---|---|
| Percentage of Participants Reporting Adverse Events (AEs) up to 1 Month After Vaccination | 23.9 ± 18.3 | 7.9 ± 4.7 | 6.5 ± 3.5 | 4.4 ± 2.0 |
An SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | Cohort 1: 20vPnC: >=15 to <24 Months | Cohort 2: 20vPnC: >=2 to <5 Years | Cohort 3: 20vPnC: >=5 to <10 Years | Cohort 4: 20vPnC: >=10 to <18 Years |
|---|---|---|---|---|
| Percentage of Participants Reporting Serious Adverse Events (SAEs) up to 6 Months After Vaccination | 1.0 (0.1 to 3.4) | 0 (0.0 to 1.7) | 0 (0.0 to 1.8) | 1.5 (0.3 to 4.2) |
An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | Cohort 1: 20vPnC: >=15 to <24 Months | Cohort 2: 20vPnC: >=2 to <5 Years | Cohort 3: 20vPnC: >=5 to <10 Years | Cohort 4: 20vPnC: >=10 to <18 Years |
|---|---|---|---|---|
| Percentage of Participants Reporting Newly Diagnosed Chronic Medical Conditions (NDCMCs) up to 6 Months After Vaccination | 3.3 (1.4 to 6.8) | 0.5 (0.0 to 2.6) | 0.5 (0.0 to 2.7) | 1.0 (0.1 to 3.5) |
Pneumococcal serotype-specific IgG concentrations were measured from serum samples for the 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding 2-sided 95% CIs (based on Student's t distribution). Superiority of IgG concentration 1 month after 20vPnC to before vaccination for each serotype was demonstrated if the 95% lower CI of GMFR was \>1.
| Fold rise | Cohort 1: 20vPnC: >=15 to <24 Months | Cohort 2: 20vPnC: >=2 to <5 Years |
|---|---|---|
| Serotype 8 | 113.4 (93.2 to 137.9) | 107.0 (86.1 to 133.0) |
| Serotype 10A | 83.2 (69.1 to 100.2) | 106.7 (86.2 to 132.0) |
| Serotype 11A | 62.7 (49.9 to 78.8) | 43.6 (33.2 to 57.1) |
| Serotype 12F | 27.9 (22.9 to 34.1) | 36.6 (30.1 to 44.7) |
| Serotype 15B | 52.1 (43.2 to 62.8) | 73.3 (58.7 to 91.5) |
| Serotype 22F | 1847.7 (1481.3 to 2304.5) | 796.2 (577.1 to 1098.4) |
| Serotype 33F | 113.5 (92.5 to 139.2) | 78.3 (61.6 to 99.5) |
Pneumococcal serotype-specific OPA titers were measured from serum samples for 7 the additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding 2-sided 95% CIs (based on the Student's t distribution). Superiority of OPA titers 1 month after 20vPnC to before vaccination for each serotype was demonstrated if the 95% lower CI of the GMFR was \>1.
| Fold rise | Cohort 3: 20vPnC: >=5 to <10 Years | Cohort 4: 20vPnC: >=10 to <18 Years |
|---|---|---|
| Serotype 8 | 106.5 (79.9 to 142.0) | 86.3 (64.2 to 115.9) |
| Serotype 10A | 30.6 (20.1 to 46.6) | 33.5 (22.3 to 50.1) |
| Serotype 11A | 11.6 (7.6 to 17.7) | 14.9 (10.2 to 21.8) |
| Serotype 12F | 463.6 (332.3 to 646.7) | 454.1 (333.3 to 618.7) |
| Serotype 15B | 380.8 (228.3 to 635.2) | 499.0 (338.7 to 735.3) |
| Serotype 22F | 128.5 (76.7 to 215.3) | 111.2 (67.1 to 184.3) |
| Serotype 33F | 14.2 (10.9 to 18.4) | 11.5 (8.9 to 14.9) |
Pneumococcal serotype-specific IgG concentrations were measured from serum samples for the 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. Percentage of participants with predefined level (\>=0.35 micrograms per milliliter) of IgG concentration for the 7 additional 20vPnC serotypes was presented. 2-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | Cohort 1: 20vPnC: >=15 to <24 Months |
|---|---|
| Serotype 8 | 100.0 ± 98.1 |
| Serotype 10A | 83.2 ± 77.1 |
| Serotype 11A | 93.2 ± 88.6 |
| Serotype 12F | 40.0 ± 33.0 |
| Serotype 15B | 83.7 ± 77.6 |
| Serotype 22F | 98.9 ± 96.2 |
| Serotype 33F | 92.6 ± 87.9 |
Pneumococcal serotype-specific OPA titers were measured from serum samples for 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. Percentage of participants with \>=4-fold rise in serotype-specific OPA titers from before vaccination to 1 month after vaccination with 20vPnC and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented. OPA titers were measured in a randomized subset of samples in Cohort 2 for this outcome measure.
| Percentage of participants | Cohort 2: 20vPnC: >=2 to <5 Years | Cohort 3: 20vPnC: >=5 to <10 Years | Cohort 4: 20vPnC: >=10 to <18 Years |
|---|---|---|---|
| Serotype 8 | 93.2 (84.9 to 97.8) | 92.2 (86.7 to 95.9) | 89.1 (83.5 to 93.3) |
| Serotype 10A | 84.9 (74.6 to 92.2) | 80.6 (72.9 to 86.9) | 81.7 (74.3 to 87.7) |
| Serotype 11A | 86.5 (74.2 to 94.4) | 66.2 (57.6 to 74.1) | 62.6 (54.5 to 70.2) |
| Serotype: 12F | 94.6 (86.7 to 98.5) | 96.8 (92.6 to 98.9) | 94.5 (89.8 to 97.5) |
| Serotype: 15B | 88.2 (78.7 to 94.4) | 89.4 (83.2 to 94.0) | 93.9 (89.1 to 97.0) |
| Serotype: 22F | 86.8 (76.4 to 93.8) | 87.6 (80.9 to 92.6) | 81.0 (74.2 to 86.6) |
| Serotype: 33F | 71.2 (59.4 to 81.2) | 79.9 (72.4 to 86.1) | 75.3 (67.8 to 81.8) |
Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F; and 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMCs the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding 2-sided 95% CIs (based on the Student's t distribution).
| Micrograms per milliliter | Cohort 1: 20vPnC: >=15 to <24 Months | Cohort 2: 20vPnC: >=2 to <5 Years | Cohort 3: 20vPnC: >=5 to <10 Years | Cohort 4: 20vPnC: >=10 to <18 Years |
|---|---|---|---|---|
| Before Vaccination, Serotype 1 | 0.43 (0.37 to 0.49) | 0.20 (0.17 to 0.24) | 0.12 (0.10 to 0.14) | 0.09 (0.08 to 0.11) |
| 1 Month after Vaccination, Serotype 1 | 1.46 (1.28 to 1.67) | 4.21 (3.62 to 4.90) | 5.86 (5.15 to 6.67) | 4.04 (3.32 to 4.93) |
| Before Vaccination, Serotype 3 | 0.14 (0.12 to 0.16) | 0.08 (0.06 to 0.10) | 0.22 (0.17 to 0.30) | 0.15 (0.11 to 0.20) |
| 1 Month after Vaccination, Serotype 3 | 0.54 (0.47 to 0.61) | 1.21 (1.04 to 1.42) | 1.32 (1.16 to 1.50) | 0.62 (0.52 to 0.76) |
| Before Vaccination, Serotype 4 | 0.61 (0.52 to 0.72) | 0.30 (0.25 to 0.37) | 0.13 (0.11 to 0.16) | 0.12 (0.10 to 0.15) |
| 1 Month after Vaccination, Serotype 4 | 2.59 (2.27 to 2.96) | 8.37 (7.28 to 9.62) | 9.76 (8.54 to 11.15) | 6.37 (5.39 to 7.53) |
| Before Vaccination, Serotype 5 | 0.43 (0.36 to 0.50) | 0.18 (0.15 to 0.22) | 0.07 (0.06 to 0.08) | 0.04 (0.03 to 0.06) |
| 1 Month after Vaccination, Serotype 5 | 1.53 (1.32 to 1.77) | 5.09 (4.32 to 5.99) | 7.50 (6.52 to 8.63) | 2.58 (1.88 to 3.53) |
| Before Vaccination, Serotype 6A | 1.61 (1.38 to 1.88) | 0.71 (0.58 to 0.88) | 0.50 (0.39 to 0.65) | 0.28 (0.22 to 0.37) |
| 1 Month after Vaccination, Serotype 6A | 7.59 (6.67 to 8.63) | 31.99 (27.85 to 36.75) | 46.28 (39.90 to 53.67) | 20.03 (15.39 to 26.07) |
| Before Vaccination, Serotype 6B | 0.85 (0.71 to 1.02) | 0.52 (0.42 to 0.63) | 0.26 (0.20 to 0.32) | 0.40 (0.31 to 0.51) |
| 1 Month after Vaccination, Serotype 6B | 4.27 (3.69 to 4.94) | 17.78 (15.43 to 20.48) | 32.45 (27.90 to 37.74) | 38.82 (31.49 to 47.86) |
| Before Vaccination, Serotype 7F | 1.17 (1.03 to 1.33) | 0.51 (0.44 to 0.60) | 0.18 (0.16 to 0.21) | 0.11 (0.08 to 0.14) |
| 1 Month after Vaccination, Serotype 7F | 3.53 (3.16 to 3.94) | 6.42 (5.69 to 7.24) | 7.92 (7.03 to 8.93) | 3.19 (2.65 to 3.85) |
| Before Vaccination, Serotype 9V | 0.71 (0.61 to 0.83) | 0.35 (0.28 to 0.42) | 0.14 (0.11 to 0.17) | 0.14 (0.11 to 0.18) |
| 1 Month after Vaccination, Serotype 9V | 2.70 (2.35 to 3.09) | 7.94 (6.83 to 9.24) | 10.86 (9.41 to 12.54) | 7.67 (6.52 to 9.02) |
| Before Vaccination, Serotype 14 | 1.53 (1.31 to 1.79) | 0.66 (0.53 to 0.81) | 0.42 (0.33 to 0.53) | 0.29 (0.23 to 0.37) |
| 1 Month after Vaccination, Serotype 14 | 4.42 (3.82 to 5.12) | 14.60 (12.44 to 17.13) | 28.54 (24.77 to 32.89) | 28.17 (23.90 to 33.21) |
| Before Vaccination, Serotype 18C | 0.65 (0.55 to 0.76) | 0.26 (0.21 to 0.32) | 0.12 (0.09 to 0.14) | 0.13 (0.11 to 0.17) |
| 1 Month after Vaccination, Serotype 18C | 2.69 (2.32 to 3.12) | 7.07 (6.01 to 8.32) | 10.83 (9.53 to 12.30) | 8.61 (7.34 to 10.10) |
| Before Vaccination, Serotype 19A | 0.47 (0.38 to 0.58) | 0.52 (0.40 to 0.68) | 0.78 (0.58 to 1.04) | 0.55 (0.43 to 0.70) |
| 1 Month after Vaccination, Serotype 19A | 3.29 (2.89 to 3.76) | 12.48 (10.76 to 14.48) | 13.65 (11.96 to 15.59) | 8.89 (7.29 to 10.84) |
| Before Vaccination, Serotype 19F | 0.80 (0.67 to 0.94) | 0.56 (0.44 to 0.71) | 0.96 (0.70 to 1.32) | 0.82 (0.63 to 1.06) |
| 1 Month after Vaccination, Serotype 19F | 4.16 (3.61 to 4.79) | 12.50 (10.48 to 14.91) | 14.62 (12.32 to 17.36) | 6.55 (5.60 to 7.66) |
| Before Vaccination, Serotype 23F | 0.96 (0.79 to 1.18) | 0.90 (0.71 to 1.15) | 0.82 (0.64 to 1.06) | 0.61 (0.48 to 0.78) |
| 1 Month after Vaccination, Serotype 23F | 5.35 (4.55 to 6.30) | 16.18 (13.75 to 19.04) | 22.69 (19.40 to 26.53) | 19.16 (16.31 to 22.51) |
| Before Vaccination, Serotype 8 | 0.04 (0.03 to 0.05) | 0.05 (0.04 to 0.06) | 0.08 (0.07 to 0.10) | 0.16 (0.12 to 0.20) |
| 1 Month after Vaccination, Serotype 8 | 4.66 (4.17 to 5.22) | 5.08 (4.45 to 5.80) | 4.65 (4.05 to 5.34) | 4.26 (3.67 to 4.94) |
| Before Vaccination, Serotype 10A | 0.01 (0.01 to 0.02) | 0.03 (0.02 to 0.03) | 0.07 (0.06 to 0.09) | 0.15 (0.12 to 0.19) |
| 1 Month after Vaccination, Serotype 10A | 1.23 (1.02 to 1.48) | 2.76 (2.28 to 3.34) | 3.98 (3.25 to 4.88) | 5.35 (4.20 to 6.81) |
| Before Vaccination, Serotype 11A | 0.03 (0.02 to 0.03) | 0.06 (0.04 to 0.08) | 0.12 (0.09 to 0.16) | 0.30 (0.23 to 0.38) |
| 1 Month after Vaccination, Serotype 11A | 1.61 (1.40 to 1.86) | 2.64 (2.25 to 3.09) | 2.80 (2.35 to 3.33) | 3.13 (2.60 to 3.77) |
| Before Vaccination, Serotype 12F | 0.01 (0.01 to 0.01) | 0.01 (0.01 to 0.01) | 0.01 (0.01 to 0.01) | 0.01 (0.01 to 0.01) |
| 1 Month after Vaccination, Serotype 12F | 0.22 (0.18 to 0.27) | 0.38 (0.31 to 0.46) | 0.36 (0.29 to 0.44) | 0.28 (0.22 to 0.34) |
| Before Vaccination, Serotype 15B | 0.02 (0.02 to 0.03) | 0.05 (0.04 to 0.07) | 0.20 (0.15 to 0.27) | 0.35 (0.27 to 0.45) |
| 1 Month after Vaccination, Serotype 15B | 1.17 (0.97 to 1.40) | 3.96 (3.12 to 5.03) | 10.74 (8.49 to 13.60) | 18.79 (15.16 to 23.28) |
| Before Vaccination, Serotype 22F | 0.01 (0.00 to 0.01) | 0.02 (0.01 to 0.02) | 0.08 (0.06 to 0.11) | 0.14 (0.11 to 0.19) |
| 1 Month after Vaccination, Serotype 22F | 9.57 (8.12 to 11.29) | 12.46 (10.82 to 14.35) | 15.68 (13.45 to 18.29) | 12.36 (10.38 to 14.72) |
| Before Vaccination, Serotype 33F | 0.02 (0.01 to 0.02) | 0.04 (0.03 to 0.05) | 0.10 (0.08 to 0.12) | 0.18 (0.14 to 0.22) |
| 1 Month after Vaccination, Serotype 33F | 1.91 (1.60 to 2.27) | 3.16 (2.63 to 3.79) | 3.87 (3.24 to 4.61) | 3.93 (3.25 to 4.75) |
Pneumococcal serotype-specific IgG concentrations were measured from serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding 2-sided 95% CIs (based on the Student's t distribution).
| Fold rise | Cohort 1: 20vPnC: >=15 to <24 Months | Cohort 2: 20vPnC: >=2 to <5 Years |
|---|---|---|
| Serotype 1 | 3.4 (3.0 to 3.9) | 20.6 (17.2 to 24.7) |
| Serotype 3 | 3.9 (3.4 to 4.5) | 14.9 (12.4 to 17.9) |
| Serotype 4 | 4.3 (3.7 to 5.0) | 27.6 (22.7 to 33.5) |
| Serotype 5 | 3.6 (3.1 to 4.2) | 28.2 (23.0 to 34.6) |
| Serotype 6A | 4.8 (4.1 to 5.6) | 44.9 (35.8 to 56.3) |
| Serotype 6B | 5.0 (4.3 to 5.9) | 34.5 (28.3 to 42.0) |
| Serotype 7F | 3.0 (2.7 to 3.4) | 12.5 (10.5 to 14.9) |
| Serotype 9V | 3.8 (3.3 to 4.4) | 23.0 (19.0 to 27.8) |
| Serotype 14 | 2.9 (2.5 to 3.3) | 22.2 (18.0 to 27.4) |
| Serotype 18C | 4.2 (3.6 to 4.9) | 27.2 (22.5 to 32.9) |
| Serotype 19A | 6.9 (5.7 to 8.4) | 24.1 (19.0 to 30.6) |
| Serotype 19F | 5.2 (4.4 to 6.3) | 22.3 (17.2 to 28.8) |
| Serotype 23F | 5.6 (4.8 to 6.6) | 17.9 (14.6 to 21.9) |
Pneumococcal serotype-specific IgG concentrations were measured from serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F; and 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding 2-sided 95% CIs (based on the Student's t distribution).
| Fold rise | Cohort 3: 20vPnC: >=5 to <10 Years | Cohort 4: 20vPnC: >=10 to <18 Years |
|---|---|---|
| Serotype 1 | 49.4 (41.6 to 58.6) | 44.2 (37.0 to 52.9) |
| Serotype 3 | 5.9 (4.6 to 7.5) | 4.3 (3.5 to 5.2) |
| Serotype 4 | 74.1 (61.4 to 89.4) | 52.0 (42.3 to 64.0) |
| Serotype 5 | 107.0 (89.4 to 128.2) | 59.3 (47.6 to 73.9) |
| Serotype 6A | 91.9 (67.7 to 124.9) | 72.5 (54.9 to 95.7) |
| Serotype 6B | 127.9 (101.0 to 162.0) | 99.5 (77.1 to 128.3) |
| Serotype 7F | 42.9 (36.1 to 51.1) | 30.0 (24.0 to 37.6) |
| Serotype 9V | 80.3 (64.3 to 100.3) | 54.2 (42.7 to 68.9) |
| Serotype 14 | 68.4 (53.4 to 87.7) | 96.7 (76.6 to 122.1) |
| Serotype 18C | 93.7 (76.9 to 114.1) | 64.5 (52.3 to 79.4) |
| Serotype 19A | 17.6 (13.2 to 23.4) | 16.2 (13.1 to 20.0) |
| Serotype 19F | 15.2 (10.5 to 22.0) | 8.0 (6.0 to 10.7) |
| Serotype 23F | 27.6 (21.0 to 36.3) | 31.4 (23.8 to 41.5) |
| Serotype 8 | 55.2 (44.8 to 67.9) | 27.3 (21.9 to 33.9) |
| Serotype 10A | 54.8 (44.4 to 67.7) | 35.9 (29.3 to 43.9) |
| Serotype 11A | 23.6 (18.6 to 29.9) | 10.5 (8.5 to 12.9) |
| Serotype 12F | 31.9 (26.7 to 38.3) | 21.4 (17.6 to 26.0) |
| Serotype 15B | 52.6 (41.3 to 66.9) | 53.8 (43.1 to 67.1) |
| Serotype 22F | 187.7 (134.6 to 261.7) | 86.2 (64.9 to 114.4) |
| Serotype 33F | 39.3 (31.6 to 49.0) | 22.4 (18.2 to 27.6) |
Pneumococcal serotype-specific OPA titers were measured from serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F; and 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding 2-sided 95% CIs (based on the Student's t distribution). OPA titers were measured in a randomized subset of serum samples in Cohorts 1 and 2. OPA titers for the 13vPnC serotypes were measured in a randomized subset of serum samples in Cohorts 3 and 4.
| Titer | Cohort 1: 20vPnC: >=15 to <24 Months | Cohort 2: 20vPnC: >=2 to <5 Years | Cohort 3: 20vPnC: >=5 to <10 Years | Cohort 4: 20vPnC: >=10 to <18 Years |
|---|---|---|---|---|
| Before Vaccination, Serotype 1 | 14 (11 to 18) | 12 (10 to 14) | 10 (9 to 11) | 11 (9 to 12) |
| 1 Month after Vaccination, Serotype 1 | 57 (39 to 84) | 360 (272 to 476) | 548 (455 to 660) | 396 (302 to 519) |
| Before Vaccination, Serotype 3 | 21 (15 to 29) | 15 (11 to 22) | 29 (22 to 40) | 19 (14 to 24) |
| 1 Month after Vaccination, Serotype 3 | 80 (62 to 103) | 150 (116 to 195) | 155 (135 to 178) | 105 (88 to 124) |
| Before Vaccination, Serotype 4 | 42 (24 to 75) | 34 (19 to 62) | 43 (27 to 67) | 34 (22 to 51) |
| 1 Month after Vaccination, Serotype 4 | 563 (342 to 927) | 1729 (1188 to 2516) | 2328 (1942 to 2789) | 2290 (1822 to 2878) |
| Before Vaccination, Serotype 5 | 18 (16 to 21) | 17 (15 to 20) | 15 (15 to 15) | 15 (15 to 16) |
| 1 Month after Vaccination, Serotype 5 | 51 (38 to 68) | 198 (143 to 276) | 385 (324 to 458) | 216 (159 to 294) |
| Before Vaccination, Serotype 6A | 137 (77 to 243) | 96 (55 to 168) | 74 (51 to 106) | 64 (44 to 91) |
| 1 Month after Vaccination, Serotype 6A | 1707 (1144 to 2547) | 5283 (3954 to 7060) | 8268 (6617 to 10331) | 9434 (7616 to 11686) |
| Before Vaccination, Serotype 6B | 110 (67 to 182) | 126 (72 to 219) | 156 (99 to 244) | 237 (155 to 363) |
| 1 Month after Vaccination, Serotype 6B | 943 (611 to 1455) | 3273 (2390 to 4482) | 6569 (5367 to 8040) | 10085 (8263 to 12309) |
| Before Vaccination, Serotype 7F | 705 (492 to 1010) | 996 (748 to 1327) | 541 (410 to 713) | 516 (381 to 698) |
| 1 Month after Vaccination, Serotype 7F | 2635 (2105 to 3297) | 3409 (2552 to 4556) | 3981 (3446 to 4598) | 3326 (2878 to 3843) |
| Before Vaccination, Serotype 9V | 649 (350 to 1204) | 323 (202 to 515) | 410 (289 to 580) | 469 (330 to 667) |
| 1 Month after Vaccination, Serotype 9V | 7686 (5718 to 10332) | 7210 (4781 to 10876) | 11717 (9262 to 14823) | 9627 (7492 to 12369) |
| Before Vaccination, Serotype 14 | 242 (151 to 387) | 300 (186 to 484) | 246 (172 to 353) | 97 (65 to 145) |
| 1 Month after Vaccination, Serotype 14 | 1018 (748 to 1385) | 2506 (1932 to 3249) | 4610 (3688 to 5762) | 3925 (3153 to 4885) |
| Before Vaccination, Serotype 18C | 300 (147 to 613) | 139 (69 to 277) | 152 (89 to 261) | 73 (45 to 119) |
| 1 Month after Vaccination, Serotype 18C | 3749 (2740 to 5131) | 5344 (3809 to 7498) | 6766 (5585 to 8197) | 3617 (2816 to 4645) |
| Before Vaccination, Serotype 19A | 138 (71 to 271) | 84 (45 to 156) | 117 (76 to 181) | 66 (44 to 100) |
| 1 Month after Vaccination, Serotype 19A | 1708 (1192 to 2448) | 2640 (1943 to 3587) | 2162 (1786 to 2618) | 2212 (1801 to 2717) |
| Before Vaccination, Serotype 19F | 44 (31 to 61) | 44 (31 to 61) | 91 (66 to 125) | 57 (44 to 73) |
| 1 Month after Vaccination, Serotype 19F | 267 (169 to 421) | 928 (618 to 1394) | 1095 (810 to 1479) | 551 (401 to 757) |
| Before Vaccination, Serotype 23F | 139 (67 to 288) | 206 (108 to 394) | 87 (53 to 145) | 46 (29 to 73) |
| 1 Month after Vaccination, Serotype 23F | 1936 (1385 to 2707) | 2493 (1757 to 3539) | 2213 (1751 to 2797) | 1842 (1391 to 2439) |
| Before Vaccination, Serotype 8 | 30 (24 to 39) | 39 (29 to 54) | 34 (28 to 42) | 35 (28 to 43) |
| 1 Month after Vaccination, Serotype 8 | 4758 (3763 to 6016) | 4428 (3467 to 5654) | 3870 (3302 to 4535) | 3125 (2680 to 3642) |
| Before Vaccination, Serotype 10A | 92 (60 to 141) | 275 (160 to 472) | 745 (519 to 1071) | 554 (395 to 777) |
| 1 Month after Vaccination, Serotype 10A | 10626 (7825 to 14429) | 14345 (10473 to 19649) | 21102 (17238 to 25833) | 17417 (14301 to 21214) |
| Before Vaccination, Serotype 11A | 88 (60 to 127) | 436 (237 to 800) | 1347 (962 to 1887) | 765 (543 to 1076) |
| 1 Month after Vaccination, Serotype 11A | 13350 (10540 to 16910) | 14093 (9904 to 20054) | 16882 (13650 to 20880) | 11677 (9751 to 13982) |
| Before Vaccination, Serotype 12F | 38 (29 to 50) | 37 (27 to 50) | 48 (38 to 60) | 46 (36 to 59) |
| 1 Month after Vaccination, Serotype 12F | 16924 (13400 to 21376) | 13257 (9463 to 18572) | 23860 (19002 to 29959) | 20250 (16861 to 24320) |
| Before Vaccination, Serotype 15B | 30 (21 to 45) | 111 (63 to 197) | 79 (54 to 115) | 45 (33 to 61) |
| 1 Month after Vaccination, Serotype 15B | 22951 (17380 to 30307) | 27095 (19557 to 37538) | 25729 (19647 to 33695) | 21496 (16697 to 27672) |
| Before Vaccination, Serotype: 22F | 21 (13 to 33) | 104 (55 to 194) | 259 (170 to 394) | 243 (161 to 366) |
| 1 Month after Vaccination, Serotype 22F | 22464 (16840 to 29967) | 25573 (18096 to 36141) | 33615 (26198 to 43130) | 27922 (22622 to 34463) |
| Before Vaccination, Serotype: 33F | 1154 (861 to 1548) | 2179 (1694 to 2804) | 3334 (2847 to 3905) | 2895 (2448 to 3424) |
| 1 Month after Vaccination, Serotype 33F | 23431 (17375 to 31598) | 28076 (19255 to 40938) | 45921 (36768 to 57353) | 32363 (26219 to 39946) |
Pneumococcal serotype-specific OPA titers were measured from serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F; and 7 additional 20vPnC serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding 2-sided 95% CIs (based on the Student's t distribution). OPA titers measured in a randomized subset of serum samples in Cohorts 1 and 2 for this outcome measure.
| Fold rise | Cohort 1: 20vPnC: >=15 to <24 Months | Cohort 2: 20vPnC: >=2 to <5 Years |
|---|---|---|
| Serotype 1 | 4.1 (2.9 to 6.0) | 29.8 (21.2 to 41.9) |
| Serotype 3 | 3.7 (2.6 to 5.3) | 9.6 (7.1 to 13.1) |
| Serotype 4 | 13.2 (7.0 to 25.0) | 50.0 (26.7 to 93.6) |
| Serotype 5 | 2.8 (2.0 to 3.8) | 11.4 (8.2 to 16.0) |
| Serotype 6A | 12.7 (8.1 to 20.0) | 52.9 (30.8 to 90.9) |
| Serotype 6B | 7.8 (4.6 to 13.2) | 24.4 (14.4 to 41.2) |
| Serotype 7F | 3.6 (2.5 to 5.2) | 3.6 (2.7 to 4.8) |
| Serotype 9V | 11.5 (6.2 to 21.3) | 23.1 (14.7 to 36.5) |
| Serotype 14 | 3.9 (2.5 to 6.1) | 8.3 (5.1 to 13.4) |
| Serotype 18C | 12.7 (6.6 to 24.5) | 40.6 (20.7 to 79.6) |
| Serotype 19A | 11.1 (6.2 to 19.8) | 33.5 (17.3 to 65.0) |
| Serotype 19F | 5.7 (3.3 to 9.7) | 21.0 (13.0 to 33.9) |
| Serotype 23F | 12.5 (6.7 to 23.6) | 10.7 (6.2 to 18.5) |
| Serotype 8 | 155.9 (110.4 to 220.2) | 105.4 (67.6 to 164.3) |
| Serotype 10A | 121.7 (74.7 to 198.4) | 53.3 (28.7 to 99.0) |
| Serotype 11A | 161.4 (115.7 to 225.2) | 34.7 (17.1 to 70.4) |
| Serotype 12F | 437.2 (307.0 to 622.7) | 319.9 (193.9 to 527.9) |
| Serotype 15B | 717.6 (449.8 to 1144.6) | 294.4 (149.1 to 581.3) |
| Serotype 22F | 983.6 (580.9 to 1665.5) | 224.6 (104.9 to 480.9) |
| Serotype 33F | 18.8 (13.1 to 27.2) | 12.4 (7.4 to 20.7) |
Pneumococcal serotype-specific OPA titers were measured for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. GMFR = geometric mean of fold rise from before vaccination on Day 1 to 1 month after vaccination with 20vPnC. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding 2-sided 95% CIs (based on the Student's t distribution). OPA titers for the 13vPnC serotypes were measured in a randomized subset of serum samples in Cohorts 3 and 4.
| Fold rise | Cohort 3: 20vPnC: >=5 to <10 Years | Cohort 4: 20vPnC: >=10 to <18 Years |
|---|---|---|
| Serotype 1 | 55.2 (45.1 to 67.4) | 37.3 (28.7 to 48.6) |
| Serotype 3 | 5.3 (3.9 to 7.2) | 5.8 (4.5 to 7.5) |
| Serotype 4 | 50.2 (31.6 to 79.5) | 65.6 (41.4 to 103.7) |
| Serotype 5 | 26.7 (22.4 to 31.8) | 14.4 (10.5 to 19.6) |
| Serotype 6A | 110.3 (68.7 to 177.1) | 147.9 (96.0 to 228.0) |
| Serotype 6B | 38.8 (22.7 to 66.3) | 42.0 (26.1 to 67.6) |
| Serotype 7F | 7.0 (5.3 to 9.3) | 6.2 (4.4 to 8.8) |
| Serotype 9V | 28.9 (19.7 to 42.5) | 20.4 (13.4 to 31.0) |
| Serotype 14 | 18.1 (12.2 to 26.8) | 38.9 (25.1 to 60.3) |
| Serotype 18C | 46.2 (26.8 to 79.6) | 47.3 (28.7 to 78.0) |
| Serotype 19A | 17.5 (10.8 to 28.3) | 33.1 (20.7 to 53.1) |
| Serotype 19F | 11.7 (7.4 to 18.5) | 10.0 (6.7 to 15.0) |
| Serotype 23F | 26.9 (16.3 to 44.5) | 39.4 (23.7 to 65.7) |
Collected over Local reactions and systemic events (systematic assessment): within 7 days after vaccination; SAEs (non-systematic assessment): from Day 1 up to 6 months after vaccination and other AEs (non-systematic assessment): from Day1 up to 1 month after vaccination. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: 20vPnC: >=15 to <24 Months | 0/209 (0%) | 2/209 (1%) | 173/209 (82.8%) |
| Cohort 2: 20vPnC: >=2 to <5 Years | 0/216 (0%) | 0/216 (0%) | 163/216 (75.5%) |
| Cohort 3: 20vPnC: >=5 to <10 Years | 0/201 (0%) | 0/201 (0%) | 178/201 (88.6%) |
| Cohort 4: 20vPnC: >=10 to <18 Years | 0/205 (0%) | 3/205 (1.5%) | 186/205 (90.7%) |
| Event | Cohort 1: 20vPnC: >=15 to <24 Months | Cohort 2: 20vPnC: >=2 to <5 Years | Cohort 3: 20vPnC: >=5 to <10 Years | Cohort 4: 20vPnC: >=10 to <18 Years |
|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/209 | 0/216 | 0/201 | 1/205 |
| Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/209 | 0/216 | 0/201 | 1/205 |
| HeadacheNervous system disorders | 0/209 | 0/216 | 0/201 | 1/205 |
| Near drowningInjury, poisoning and procedural complications | 1/209 | 0/216 | 0/201 | 0/205 |
| Febrile convulsionNervous system disorders | 1/209 | 0/216 | 0/201 | 0/205 |
| Event | Cohort 1: 20vPnC: >=15 to <24 Months | Cohort 2: 20vPnC: >=2 to <5 Years | Cohort 3: 20vPnC: >=5 to <10 Years | Cohort 4: 20vPnC: >=10 to <18 Years |
|---|---|---|---|---|
| Injection site pain (PAIN)General disorders | 107/209 | 142/216 | 165/201 | 168/205 |
| Irritability (IRRITABILITY)Psychiatric disorders | 126/209 | 0/216 | 0/201 | 0/205 |
| Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 0/209 | 57/216 | 78/201 | 99/205 |
| Hypersomnia (INCREASED SLEEP)Nervous system disorders | 85/209 | 0/216 | 0/201 | 0/205 |
| Injection site erythema (REDNESS)General disorders | 77/209 | 84/216 | 74/201 | 31/205 |
| Fatigue (FATIGUE)General disorders | 0/209 | 80/216 | 56/201 | 57/205 |
| Headache (HEADACHE)Nervous system disorders | 0/209 | 12/216 | 37/201 | 60/205 |
| Injection site swelling (SWELLING)General disorders | 45/209 | 50/216 | 54/201 | 32/205 |
| Decreased appetite (DECREASED APPETITE)Metabolism and nutrition disorders | 51/209 | 0/216 | 0/201 | 0/205 |
| Pyrexia (FEVER)General disorders | 24/209 | 7/216 | 1/201 | 0/205 |
Enrolled population included all participants who signed informed consent form (ICF).
| Age, Customized(Participants) | Cohort 1: 20vPnC: >=15 to <24 Months | Cohort 2: 20vPnC: >=2 to <5 Years | Cohort 3: 20vPnC: >=5 to <10 Years | Cohort 4: 20vPnC: >=10 to <18 Years | Total |
|---|---|---|---|---|---|
| 28 Days to 23 Months | 210 | 0 | 0 | 0 | 210 |
| 2 Years to 5 Years | 0 | 219 | 28 | 0 | 247 |
| 6 Years to 11 Years | 0 | 0 | 175 | 51 | 226 |
| 12 Years to 18 Years | 0 | 0 | 0 | 156 | 156 |
| Sex: Female, Male(Participants) | Cohort 1: 20vPnC: >=15 to <24 Months | Cohort 2: 20vPnC: >=2 to <5 Years | Cohort 3: 20vPnC: >=5 to <10 Years | Cohort 4: 20vPnC: >=10 to <18 Years | Total |
|---|---|---|---|---|---|
| Female | 93 | 111 | 94 | 91 | 389 |
| Male | 117 | 108 | 109 | 116 | 450 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: 20vPnC: >=15 to <24 Months | Cohort 2: 20vPnC: >=2 to <5 Years | Cohort 3: 20vPnC: >=5 to <10 Years | Cohort 4: 20vPnC: >=10 to <18 Years | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 35 | 46 | 32 | 45 | 158 |
| Not Hispanic or Latino | 173 | 173 | 169 | 161 | 676 |
| Unknown or Not Reported | 2 | 0 | 2 | 1 | 5 |
| Race (NIH/OMB)(Participants) | Cohort 1: 20vPnC: >=15 to <24 Months | Cohort 2: 20vPnC: >=2 to <5 Years | Cohort 3: 20vPnC: >=5 to <10 Years | Cohort 4: 20vPnC: >=10 to <18 Years | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 3 | 0 | 0 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 1 |
| Black or African American | 26 | 26 | 22 | 17 | 91 |
| White | 169 | 175 | 176 | 180 | 700 |
| More than one race | 10 | 14 | 5 | 9 | 38 |
| Unknown or Not Reported | 2 | 3 | 0 | 0 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Dec 2020 to primary completion in Apr 2022, 16 months.
Results were first posted in Apr 2023, 1 year after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 16 months is above that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine